Originally Posted by
MAC
I'm not one for speculating on the short term either Hancock’s, who really knows if the FOMO set will do what they do this time or next, don't really care to be honest.
Although the SP is undervalued by 86% even by Forbar’s very conservative effort at $1.30, and that may just be a reason enough on its own for a move.
There are I think some long termer's who have holding off for an entry point, and the shareprice will only track sideways for so long, once molecular diagnostic company revenue curves take-off they tend to go quickly, and there will be a point where the insto's will all jump on board to ride that curve.
It might be this report or it might be the next, who knows, but there is certainly a lot on the horizon within the next several months to kick things uphill, Medicare coverage, VA coverage, KP contract sign up, launch of triage, maybe predict also, possibly the appointment of a distributing partner, perhaps some private insurer coverage too.
The first year of commercialisation is at a close, typically it is the second year for molecular diagnostic company products that sees the first big ramp in revenues.
I’m looking for circa 3 to 4 times the revenue we see next week to be reported at the end of year two, FY16, noting that the sales force was only really in place and up to speed for under six months of the FY15 period.